Related Experiment Videos
Eplerenone: a selective aldosterone blocker.
1Department of Pharmacology, New York Medical College, Valhalla, NY 10595, USA. Charles_Stier@nymc.edu.
Cardiovascular Drug Reviews
|August 22, 2003
Summary
Eplerenone, a selective aldosterone receptor blocker, effectively treats hypertension and reduces cardiovascular damage. It significantly lowers mortality and hospitalizations post-myocardial infarction, demonstrating therapeutic value in cardiovascular disease management.
Area of Science:
- Cardiology
- Pharmacology
- Endocrinology
Background:
- Aldosterone plays a significant role in cardiovascular physiology and disease.
- Adverse effects of aldosterone include fibrosis, inflammation, hypertension, and heart failure.
- Blocking aldosterone action is therapeutically important for managing cardiovascular conditions.
Purpose of the Study:
- To evaluate the therapeutic importance of selective aldosterone receptor blockade.
- To assess the efficacy of eplerenone in hypertension and cardiovascular disease.
- To review eplerenone's safety and tolerability profile.
Main Methods:
- Eplerenone, a selective aldosterone receptor antagonist, was studied.
- Clinical trials evaluated eplerenone in various hypertension subgroups.
- The EPHESUS trial assessed eplerenone's impact post-myocardial infarction.
Main Results:
- Eplerenone effectively lowers blood pressure and reduces end-organ damage in hypertensive patients.
- In post-myocardial infarction patients, eplerenone reduced total mortality by 15% and cardiovascular events by 13%.
- Eplerenone demonstrated a well-tolerated adverse effect profile, comparable to placebo.
Conclusions:
- Selective aldosterone blockers like eplerenone offer significant therapeutic benefits.
- Eplerenone is valuable for hypertension control and preventing cardiovascular disease.
- Eplerenone aids in preventing cardiovascular disease and associated end-organ damage.